Actively Recruiting

Phase 2
Age: 14Years - 60Years
All Genders
NCT07512700

Venetoclax Combined With CACAG Regimen Versus "3+7" Regimen in the Treatment of Acute Monocytic Leukemia

Led by Chinese PLA General Hospital · Updated on 2026-04-06

204

Participants Needed

3

Research Sites

217 weeks

Total Duration

On this page

Sponsors

C

Chinese PLA General Hospital

Lead Sponsor

A

Air Force Medical Center of PLA

Collaborating Sponsor

AI-Summary

What this Trial Is About

This study is a multicenter, randomized, prospective Phase II clinical trial designed to compare the effectiveness of two treatment approaches for patients with acute monocytic leukemia.

CONDITIONS

Official Title

Venetoclax Combined With CACAG Regimen Versus "3+7" Regimen in the Treatment of Acute Monocytic Leukemia

Who Can Participate

Age: 14Years - 60Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Voluntary participation with signed informed consent and willingness to follow study procedures
  • Age between 14 and 60 years
  • Diagnosis of acute monocytic leukemia per 2016 WHO classification, excluding acute promyelocytic leukemia
  • No history of severe allergic reactions
  • Liver function with ALT and AST less than or equal to 2.5 times the upper limit of normal (ULN) and total bilirubin less than or equal to 2 times ULN
  • Renal function with serum creatinine less than or equal to 1.5 times ULN
  • No uncontrolled infection or severe psychiatric disorder
  • Eastern Cooperative Oncology Group (ECOG) performance status 0 to 3
  • Life expectancy of at least 4 months
Not Eligible

You will not qualify if you...

  • Known allergy or contraindication to any study drug
  • Pregnancy or breastfeeding
  • Active infection
  • Long-term smoking or alcohol abuse that may affect study evaluation
  • Psychiatric illness or other condition preventing informed consent or compliance
  • Major organ surgery within 6 weeks before enrollment
  • Abnormal liver function with total bilirubin greater than 2 times ULN or ALT/AST greater than 2.5 times ULN
  • Abnormal renal function with serum creatinine greater than 1.5 times ULN
  • Any other condition deemed unsuitable for the study by the investigator such as poor compliance or substance abuse

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 3 locations

1

Air Force Medical Center, PLA

Beijing, China

Actively Recruiting

2

Chinese PLA General Hospital

Beijing, China

Actively Recruiting

3

PLA Strategic Support Force's Characteristic Medical Center

Beijing, China

Actively Recruiting

Loading map...

Research Team

L

Liping Dou, Doctor

CONTACT

D

Daihong Liu, Doctor

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here